Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 3Recruiting 3Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 1872Triple Negative Breast Neoplasms 126Neoplasms 74Ovarian Neoplasms 56Neoplasm Metastasis 55Colorectal Neoplasms 54Prostatic Neoplasms 53Lung Neoplasms 51Stomach Neoplasms 45Pancreatic Neoplasms 43Motor Activity 41Colonic Neoplasms 41Lymphedema 35Breast Cancer Female 32Advanced Breast Cancer 32Carcinoma, Non-Small-Cell Lung 31Endometrial Neoplasms 28Melanoma 27Breast Diseases 26Head and Neck Neoplasms 25Cardiotoxicity 25HER2-positive Breast Cancer 22Uterine Cervical Neoplasms 21Brain Neoplasms 21Breast Cancer Lymphedema 20Pain 19Fatigue 19Esophageal Neoplasms 19Breast Neoplasms, Male 19Urinary Bladder Neoplasms 18

Interventions

pyrotinib 1Trastuzumab 1Drug Therapy 1Docetaxel 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × HER2-positive Metastatic Breast Cancer × Breast × Clear all
NCT05042791 2024-02-09

A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

Jiangxi Provincial Cancer Hospital

Phase 2 Unknown
362 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT05188495 2022-01-12

HELP

Peking University Cancer Hospital & Institute

Unknown
60 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT04385563 2020-05-13

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
338 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡